WHI TRUST Co LLC Makes New Investment in Kalaris Therapeutics Inc. $KLRS

WHI TRUST Co LLC acquired a new position in shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 97,493 shares of the company’s stock, valued at approximately $823,000. Kalaris Therapeutics makes up approximately 0.6% of WHI TRUST Co LLC’s holdings, making the stock its 11th largest position.

A number of other large investors have also recently bought and sold shares of KLRS. Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at approximately $58,000. Bridgeway Capital Management LLC acquired a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at approximately $130,000. XTX Topco Ltd acquired a new stake in shares of Kalaris Therapeutics in the 2nd quarter valued at approximately $65,000. Belpointe Asset Management LLC acquired a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at approximately $231,000. Finally, Fortis Capital Advisors LLC acquired a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at approximately $231,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Kalaris Therapeutics Price Performance

NASDAQ:KLRS opened at $5.22 on Friday. The firm’s 50 day simple moving average is $6.58 and its 200 day simple moving average is $7.52. Kalaris Therapeutics Inc. has a one year low of $2.14 and a one year high of $11.88. The company has a market cap of $120.02 million, a PE ratio of -2.43 and a beta of 0.15.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06. Equities research analysts expect that Kalaris Therapeutics Inc. will post -2.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Wedbush assumed coverage on shares of Kalaris Therapeutics in a research note on Thursday. They issued an “outperform” rating and a $17.00 price target on the stock. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Wednesday. Wall Street Zen upgraded shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Citizens Jmp reduced their price target on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Wednesday. Finally, Morgan Stanley assumed coverage on shares of Kalaris Therapeutics in a research note on Thursday, April 16th. They issued an “overweight” rating and a $14.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Kalaris Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $15.60.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.